Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$5.70 USD
-0.10 (-1.72%)
Updated May 31, 2024 04:00 PM ET
After-Market: $5.68 -0.02 (-0.35%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
Ocular Therapeutix, Inc. [OCUL]
Reports for Purchase
Showing records 81 - 87 ( 87 total )
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2018 1Q Results Reported; Dextenza NDA Resubmission This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2017 Results Reported; Dextenza NDA Resubmission on Track in 1H18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Our Impressions of the American Academy of Ophthalmology (AAO) 2017 Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
3Q17 Results Reported; Dextenza NDA Resubmission in 1H 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2Q17 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
New CEO Commenced Employment; Restructuring Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
A Sustained Delivery Platform for Your Eyes; Initiating Coverage at Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.